Stephens downgraded shares of Lifecore Biomedical (NASDAQ:LFCR – Get Rating) from an overweight rating to an equal weight rating in a research note issued to investors on Monday, The Fly reports.
Separately, Barrington Research reduced their price target on shares of Lifecore Biomedical from $12.00 to $10.00 in a research report on Wednesday, January 11th.
Get Lifecore Biomedical alerts:Lifecore Biomedical Trading Down 6.6 %
Shares of NASDAQ:LFCR opened at $3.04 on Monday. Lifecore Biomedical has a fifty-two week low of $1.52 and a fifty-two week high of $11.95. The stock has a 50-day simple moving average of $5.80. The stock has a market cap of $92.17 million, a price-to-earnings ratio of -1.22 and a beta of 1.11.
About Lifecore Biomedical
(Get Rating)
Lifecore Biomedical, Inc engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans.
Read More
- Get a free copy of the StockNews.com research report on Lifecore Biomedical (LFCR)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Low Volume Bunge Plunge Presents an Opportunity
- Carvana May Be Able To Reach Profitability This Year
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.